费森尤斯医疗在2026年欧洲肾病学会大会展示新的肾脏研究与创新成果

Hemodiafiltration (HDF) research reinforces Fresenius Medical Care's continued leadership in advancing evidence-based dialysis care and treatment personalization

血液透析滤过（HDF）研究进一步巩固了费森尤斯医疗在推进基于证据的透析护理和治疗个性化方面的持续领导地位。

New research focuses on applying real-world evidence, patient-centered outcomes and artificial intelligence across dialysis modalities and continuity of kidney care

新研究聚焦于在透析模式和肾脏护理连续性中应用真实世界证据、以患者为中心的结局和人工智能。

A preview of kinexus, a unified digital platform intended to support home dialysis programs by connecting therapy management and care workflows

kinexus 预览，这是一个统一的数字平台，旨在通过连接治疗管理和护理工作流程来支持家庭透析计划。

BAD HOMBURG, Germany

德国巴特洪堡

,

，

May 27, 2026

2026年5月27日

/PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with kidney diseases, presents new research highlighting ongoing innovation at the European Renal Association (ERA) Congress 2026, June 3-6 in Glasgow, Scotland, and virtually. The Company highlights advancements including new hemodiafiltration research that reaffirm its leadership in evidence based and personalized dialysis care, real-world evidence to strengthen patient centered outcomes across dialysis modalities, and the application of artificial intelligence (AI) to improve patient outcomes..

/PRNewswire/ -- 全球领先的肾病产品和服务提供商费森尤斯医疗（FME），在2026年6月3日至6日于苏格兰格拉斯哥及线上举行的欧洲肾病学会（ERA）大会上展示了新的研究成果，突显其持续创新。公司重点介绍了多项进展，包括新的血液透析滤过研究，进一步巩固了其在基于证据和个性化透析护理方面的领导地位；用于加强跨透析模式以患者为中心的实际结果的真实世界证据；以及应用人工智能（AI）改善患者预后的研究成果。

'Fresenius Medical Care is focused on the research that can meaningfully advance the standard of care for people living with kidney disease,' said Charles Hugh-Jones, Global Chief Medical Officer at Fresenius Medical Care. 'At ERA Congress 2026, we continue demonstrating our Company's leadership in evidence-based hemodiafiltration research and present abstracts covering the use of real-world evidence, patient-centered outcomes and artificial intelligence that are designed to help clinicians make better informed decisions and support patients across multiple care settings.'.

费森尤斯医疗集团全球首席医疗官查尔斯·休-琼斯表示：“费森尤斯医疗集团专注于能够有意义地提高肾病患者护理标准的研究。在2026年欧洲肾病学会大会（ERA Congress 2026）上，我们将继续展示公司在基于证据的血液透析滤过研究领域的领导地位，并提交涵盖真实世界证据、以患者为中心的治疗结果以及人工智能应用的摘要，旨在帮助临床医生做出更明智的决策，并在多种护理环境中为患者提供支持。”

FME's Global Medical Office and Renal Research Institute (RRI) teams present multiple abstracts across a range of critical topics in nephrology, demonstrating how data, artificial intelligence, and patient-centered outcomes are shaping the future of kidney care.

FME的全球医疗办公室和肾脏研究所（RRI）团队在肾病学的一系列关键主题上展示了多个摘要，展示了数据、人工智能和以患者为中心的结果如何塑造肾脏护理的未来。

Key presentations include:

主要报告包括：

Impact of Matching and Weighting Strategy on Patient Retention and 3

匹配和权重策略对患者保留的影响 3

‑

‑

Year Mortality in Real

实际年死亡率

‑

‑

World Hemodialysis and Hemodiafiltration:

世界血液透析与血液透析过滤：

In a real-world analysis, hemodiafiltration was associated with lower three-year mortality risk than hemodialysis, with consistent results across different comparison methods.

在真实世界分析中，血液透析滤过与较低的三年死亡风险相关，且在不同比较方法中结果一致。

The Association Between Patient

患者之间的关联

‑

‑

Reported Dialysis Recovery Time and Missed Treatments:

报告的透析恢复时间及错过的治疗：

Hemodialysis patients who reported longer recovery times after treatment also had a higher number of missed treatments.

报告治疗后恢复时间较长的血液透析患者也错过了更多的治疗。

Clinics' Utilization of an AI-Based Model Predicting Peritoneal Dialysis Dropouts Is Associated with Lower Hospitalization Rates:

诊所利用基于人工智能的模型预测腹膜透析脱落与较低的住院率相关：

Clinics with higher use of an AI-based dashboard for identifying peritoneal dialysis patients at risk of dropping out saw lower all-cause hospitalization rates.

使用基于人工智能的仪表板识别腹膜透析患者辍疗风险的诊所，其全因住院率较低。

A High

高

‑

‑

Precision Large

精确度高

‑

‑

Language Model Approach for Abstract Screening in Systematic Reviews:

系统综述中用于摘要筛选的语言模型方法：

GPT-5 may help researchers sort through large numbers of research studies by identifying ones that are most relevant.

GPT-5可能通过识别最相关的研究，帮助研究人员筛选大量的研究论文。

In addition to these presentations, FME leaders and researchers will also be available onsite at Booth #C.210 and the Renal Research Institute's Booth #C.410 to discuss research insights, clinical collaborations, and innovations in kidney care.

除了这些展示之外，FME 的领导和研究人员还将亲临展位 #C.210 和肾脏研究所的展位 #C.410，讨论研究见解、临床合作以及肾脏护理方面的创新。

As part of its broader innovation portfolio highlighted at the Congress, FME previews kinexus, a unified digital platform for home dialysis. Designed as a single, integrated ecosystem, kinexus brings together remote therapy management and operational workflows to help simplify care processes for healthcare teams and support high-quality, personalized care for patients dialyzing at home..

作为其在大会上重点展示的更广泛创新产品组合的一部分，FME预览了kinexus，这是一个用于家庭透析的统一数字平台。Kinexus被设计为一个单一的、集成的生态系统，将远程治疗管理与操作流程结合在一起，以帮助简化医疗团队的护理流程，并支持在家中透析的患者获得高质量、个性化的护理。

To learn more about FME's presence at ERA, please click

要了解更多关于 FME 在 ERA 的相关信息，请点击

here

这里

.

。

About Fresenius Medical Care:

关于费森尤斯医疗：

Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.5 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,539 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx.

费森尤斯医疗是全球领先的肾病产品和服务提供商，全球约有450万患者定期接受透析治疗。通过其3,539家透析诊所网络，费森尤斯医疗为大约...

290,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS)..

全球290,000名患者。费森尤斯医疗护理也是透析产品（如透析机或透析器）的领先供应商。费森尤斯医疗护理在法兰克福证券交易所（FME）和纽约证券交易所（FMS）上市。

For more information visit the company's website at

欲了解更多信息，请访问公司网站

www.freseniusmedicalcare.com

www.freseniusmedicalcare.com

.

。

Disclaimer:

免责声明：

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing.

本发布包含受各种风险和不确定性影响的前瞻性陈述。由于各种因素，实际结果可能与这些前瞻性陈述中描述的结果有重大差异，这些因素包括但不限于业务、经济和竞争状况的变化、法律变更、监管批准、临床研究结果、汇率波动、诉讼或调查程序中的不确定性以及融资的可用性。

These and other risks and uncertainties are detailed in Fresenius Medical Care's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release..

这些以及其他风险和不确定性在费森尤斯医疗公司向美国证券交易委员会提交的报告中有详细说明。费森尤斯医疗公司不承担更新本新闻稿中前瞻性声明的责任。

Huma Therapeutics Limited is the digital health platform partner and legal manufacturer of kinexus. Fresenius Medical Care Deutschland GmbH acts as the authorized distributor.

Huma Therapeutics Limited 是 kinexus 的数字健康平台合作伙伴及合法制造商。Fresenius Medical Care Deutschland GmbH 担任授权经销商。

For more information about Huma Therapeutics Limited visit the company's website at

欲了解有关Huma Therapeutics Limited的更多信息，请访问该公司的网站

www.huma.com

www.huma.com

.

。

Media contact

媒体联系人

Christine Peters

克里斯汀·彼得斯

T +49 160 60 66 770

电话 +49 160 60 66 770

[email protected]

电子邮件地址

Kirsten Stratton

克里斯滕·斯特拉顿

T +1 781 929 8096

电话：+1 781 929 8096

[email protected]

电子邮件地址

Contact for analysts and investors

分析师和投资者联系人

Dr. Dominik Heger

多米尼克·赫格尔博士

T +49 6172 609 2525

电话 +49 6172 609 2525

[email protected]

电子邮件地址

www.freseniusmedicalcare.com

www.freseniusmedicalcare.com

SOURCE Fresenius Medical Care Holdings, Inc.

来源：费森尤斯医疗控股公司

21

21

%

%

more press release views with

更多新闻稿浏览量与

Request a Demo

请求演示